Amarin Completes Analysis From Huntington's Disease Program

English drugmaker Amarin has met with the FDA following the completion of a data review from its Phase III studies of Miraxion to treat Huntington’s disease.

The agency indicated that an additional Phase III trial may provide the data needed to support a new drug application.

Rick Stewart, Amarin’s CEO, said the company is determining whether to conduct the trial itself or seek a collaborative partner.